Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYCHLOROQUINE versus LEFLUNOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYCHLOROQUINE versus LEFLUNOMIDE.
Hydroxychloroquine vs LEFLUNOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxychloroquine is a 4-aminoquinoline antimalarial agent that accumulates in lysosomes and inhibits Toll-like receptor signaling, reduces cytokine production, and interferes with antigen presentation. It also inhibits heme polymerase in malarial parasites, leading to toxic heme accumulation.
Inhibits dihydroorotate dehydrogenase (DHODH), blocking de novo pyrimidine synthesis, thereby reducing lymphocyte proliferation.
400 mg orally once daily or 200 mg orally twice daily, then 200-400 mg orally once daily for maintenance, depending on indication.
100 mg PO once daily for 3 days (loading dose), then 20 mg PO once daily (maintenance); may reduce to 10 mg PO once daily if not tolerated.
None Documented
None Documented
Clinical Note
moderateLeflunomide + Digitoxin
"Leflunomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLeflunomide + Deslanoside
"Leflunomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLeflunomide + Acetyldigitoxin
"Leflunomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateLeflunomide + Ouabain
"Leflunomide may decrease the cardiotoxic activities of Ouabain."
Terminal half-life: 30-60 days (prolonged due to extensive tissue binding); clinical context: requires loading dose for rapid effect.
Terminal half-life of teriflunomide is approximately 18-19 days (range 14-58 days) due to enterohepatic recirculation; clinical significance: prolonged washout required before switching to other disease-modifying antirheumatic drugs (DMARDs) or in case of toxicity.
Primarily renal (30-60% unchanged); minor hepatic metabolism; fecal elimination accounts for ~20-30%.
Primarily fecal (~48%) and renal (~43%) as metabolites. Teriflunomide, the active metabolite, undergoes enterohepatic recirculation and is eliminated via bile and feces. Less than 1% excreted as unchanged drug.
Category A/B
Category D/X
Antimalarial / DMARD
DMARD